Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)
(2018)
Journal Article
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., MacCallum, P., Kakkar, A., Richard Hobbs, F. D., Petrou, S., Dale, J., Poole, C. J., Maraveyas, A., & Levine, M. (2018). Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20), 2017-2023. https://doi.org/10.1200/JCO.2018.78.8034
© 2018 by American Society of Clinical Oncology. Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this stud... Read More about Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D).